Tag
A living systematic review of 30 RCTs (n=1,480) finds moderate-to-large symptom reductions for MDMA in PTSD and serotonergic psychedelics in major depression and anxiety, but high risk of bias and low certainty overall; pragmatic, longer, a
The KARMA-Dep 2 trial reveals that serial ketamine infusions do not significantly outperform midazolam in reducing depressive symptoms among inpatients receiving usual psychiatric care, challenging assumptions about ketamine’s long-term ant
A 3-month RCT demonstrates that multi-species probiotic supplementation improves vagal nerve function, gut microbiome composition, and sleep quality in patients with major depression, suggesting novel gut-brain axis interventions.
This review synthesizes evidence from a randomized trial and real-world studies showing esketamine’s efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlight
A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.
